Search Results - "A G Turkina"

The EUTOS population-based registry: incidence and clinical characteristics of 2904 CML patients in 20 European Countries by Hoffmann, V S, Baccarani, M, Hasford, J, Lindoerfer, D, Burgstaller, S, Sertic, D, Costeas, P, Mayer, J, Indrak, K, Everaus, H, Koskenvesa, P, Guilhot, J, Schubert-Fritschle, G, Castagnetti, F, Di Raimondo, F, Lejniece, S, Griskevicius, L, Thielen, N, Sacha, T, Hellmann, A, Turkina, A G, Zaritskey, A, Bogdanovic, A, Sninska, Z, Zupan, I, Steegmann, J-L, Simonsson, B, Clark, R E, Covelli, A, Guidi, G, Hehlmann, R

“…This population-based registry was designed to provide robust and updated information on the characteristics and the epidemiology of chronic myeloid leukemia…”
Get full text

Successful use of long-term follow-up in patients with chronic myeloid leukemia with a deep molecular response at reduced doses of 2nd generation tyrosine kinase inhibitors: clinical cases and literature review by Gurianova, M A, Chelysheva, E Y, Shukhov, O A, Turkina, A G

“…Therapy with tyrosine kinase inhibitors (TKI) allows to achieve a deep molecular response in 6070% of patients with chronic myeloid leukemia (CML). According…”
Get full text

Results of following up patients with chronic myeloid leukemia and a deep molecular response without tyrosine kinase inhibitor therapy by Turkina, A G, Chelysheva, E Yu, Shuvaev, V A, Gusarova, G A, Bykova, A V, Shukhov, O A, Petrova, A N, Vakhrusheva, M V, Goryacheva, S R, Kolosova, L Yu, Krasikova, P S, Fominykh, M S, Martynkevich, I S, Abdullaev, A O, Sudarikov, A B, Savchenko, V G

“…To assess the results of following up patients with chronic myeloid leukemia (CML) and a deep molecular response (MR) without tyrosine kinase inhibitor (TKI)…”
Get full text

Therapeutic strategy for chronic myeloid leukemia: possibilities and prospects by Turkina, A G, Chelysheva, E Iu

“…Over the past decade the clinical introduction of agents that directionally blocks the activity of BCR-ABL tumor tyrosine kinase (TK) has changed the prognosis…”
Get full text

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib by Stromskaya, T. P, Rybalkina, E. Yu, Kruglov, S. S, Zabotina, T. N, Mechetner, E. B, Turkina, A. G, Stavrovskaya, A. A

“…Imatinib mesylate (imatinib) is a new generation preparation that is now successfully used for treatment of cancer, particularly for chemotherapy of chronic…”
Get full text

A rare case of myeloproliferative disease with t(8;13)(p11;q12) associated with eosinophilia and lymphadenopathy by Tsyba, N N, Turkina, A G, Chelysheva, E Yu, Nemchenko, I S, Kovrigina, A M, Obukhova, T N, Urnova, E S, Kuzmina, L A, Savchenko, V G

“…Myeloproliferative disease associated with FGFR1 rearrangement (8p11), which is included in the 2008 WHO Classification of Myeloid Neoplasms, is a rare and…”
Get full text

Incidence of chronic myeloid leukemia in 6 regions of Russia according to the data of the 2009-2012 population-based study by Kulikov, S M, Vinogradova, O Iu, Chelysheva, E Iu, Tishchenko, I A, Galaĭko, M A, Lazareva, O V, Senderova, O M, Pepeliaeva, V M, Meresiĭ, S V, Luchinin, A S, Ovsepian, V A, Miliutina, G I, Gavrilova, L V, Avdeeva, L B, Neverova, A L, Turkina, A G

“…To assess the main epidemiological characteristics of chronic myeloid leukemia (CML) in the Russian Federation. A planned epidemiological prospective study was…”
Get full text

Efficiency of interferon therapy in patients with essential thrombocythemia or polycythemia vera by Sokolova, M A, Turkina, A G, Melikian, A L, Sudarikov, A B, Treglazova, S A, Shukhov, O A, Gemdzhian, E G, Abdullaev, A О, Kovrigina, A M, Misyurin, A V, Pliskunova, Yu V, Ivanova, V L, Moiseeva, T N

“…To evaluate the efficiency of interferon (IFN) therapy in patients with essential thrombocythemia (ET) and polycythemia vera (PV). A total of 61 patients (41…”
Get full text

FIP1L1-PDGFRА-positive myeloproliferative disease with eosinophilia: A rare case with multiple organ dysfunction and a response to tyrosine kinase inhibitor therapy by Nemchenko, I S, Turkina, A G, Chelysheva, E Yu, Galstyan, G M, Kovrigina, A M, Khuazheva, N K, Savchenko, V G

“…The described case of FIP1L1-PDGFRА-positive myeloproliferative disease is characterized by an atypical aggressive course to develop severe specific…”
Get full text

Synchronous and metachronous myeloid and lymphoid tumors by Melikian, A L, Kolosheĭnova, T I, Goriacheva, S R, Subortseva, I N, Vakhrusheva, M V, Kolosova, E N, Sudarikov, A B, Abdullaev, A O, Dvirnyk, V N, Varlamova, E Iu, Kovrigina, A M, Turkina, A G

“…To determine the clinical features of multiple primary tumors (MPT) in patients with hemoblastoses, to develop treatment policy for synchronous and…”
Get full text

Treatment-free remission in patients with chronic myeloid leukemia: literature review by Petrova, A. N., Chelysheva, E. Yu, Turkina, A. G.

“…Tyrosine kinase inhibitors have radically changed the course of chronic myeloid leukemia, significantly increasing survival and reducing the risk of disease…”
Get full text

Changes in Bone Marrow Stromal Progenitor Cells in Patients with Hematoblastosis at the Onset of the Disease by Petinati, N. A., Shipounova, I. N., Fastova, E. A., Magomedova, A. U., Kravchenko, S. K., Chelysheva, E. Yu, Shukhov, O. A., Turkina, A. G., Sats, N. V., Drize, N. I., Parovichnikova, E. N., Savchenko, V. G.

“…Multipotent mesenchymal stromal cells (MSC) are the key regulators of hematopoiesis. We studied changes in MSC characteristics in patients with myeloid…”
Get full text

P708: CANADIAN AND RUSSIAN EXPERIENCES OF ASCIMINIB IN CHRONIC MYELOID LEUKEMIA (CML) PATIENTS WHO FAILED MULTIPLE LINES OF TYROSINE KINASE INHIBITOR (TKI) THERAPY by Khadadah, F., Turkina, A. G., Lomaia, E., Morozova, E. V., Shukhov, O. A., Petrova, A., Chitanava, T., Vlasova, J. J., Kuzmina, E., Nemchenko, I., Chelysheva, E. Y., Bykova, A., Gurianova, M., Xenocostas, A., Busque, L., Jamani, K., Cerquozzi, S., Kuruvilla, P., Kaedbey, R., Leber, B., Assouline, S., Kim, D. D. H.

Get full text

Multipotent Mesenchymal Stromal Cells in Patients with Chronic Myeloid Leukemia before Discontinuation of Tyrosine Kinase Inhibitors by Petinati, N. A., Petrova, A. N., Chelysheva, E. Yu, Shukhov, O. A., Bykova, A. V., Nemchenko, I. S., Sats, N. V., Turkina, A. G., Drize, N. I.

“…We analyzed changes in multipotent mesenchymal stromal cells of patients with chronic myeloid leukemia before discontinuation of tyrosine kinase inhibitors…”
Get full text

Dasatinib treatment of imatinib-resistant and imatinib-intolerant patients with chronic myeloid leukemia in a chronic phase by Vinogradova, O Iu, Turkina, A G, Vorontsova, A V, Chelysheva, E Iu, Gusarova, G A, Kuznetsov, S V, Goriacheva, S R, Sokolova, M A, Abakumov, E M, Stakhina, O V, Domracheva, E V, Misiurin, A V, Khoroshko, N D

“…To analyse resistance to imatinib therapy, efficacy and safety of dasatinib. A total of 18 patients with chronic myeloid leukemia (CML) in a chronic stage…”
Get full text

Studies of P-glycoprotein in chronic myelogenous leukaemia patients: expression, activity and correlations with CD34 antigen by Turkina, A G, Baryshnikov, A Y, Sedyakhina, N P, Folomeshkina, S V, Sokolova, M A, Choroshco, N D, Stavrovskaya, A A

“…Over-expression of the P-glycoprotein (Pgp), transmembrane drug efflux pump, has been shown to cause multidrug resistance of tumour cells (MDR). To investigate…”
Get more information

Role of P-glycoprotein in evolution of populations of chronic myeloid leukemia cells treated with imatinib by Stromskaya, T P, Rybalkina, E Yu, Kruglov, S S, Zabotina, T N, Mechetner, E B, Turkina, A G, Stavrovskaya, A A

“…Imatinib mesylate (imatinib) is a new generation preparation that is now successfully used for treatment of cancer, particularly for chemotherapy of chronic…”
Get full text

Second-generation tyrosine kinase inhibitors in chronic myeloid leukemia today: efficacy and safety by Tsyba, N. N., Turkina, A. G.

“…The prognosis of chronic myeloid leukemia (CML) has changed during the past two decades from a disease with an overall survival of 5 years only to one in which…”
Get full text

25 years of experience in the treatment of chronic myeloid leukemia with tyrosine kinase inhibitors: results, opportunities, questions by Tsyba, N. N., Turkina, A. G.

“…More than 25 years ago, the discovery of imatinib, the first ATP-competitive inhibitor of BCR::ABL1, the driving oncoprotein of chronic myeloid leukemia,…”
Get full text

A rare complication of imatinib mesylate therapy: drug-induced pneumonitis by Stakhina, O V, Turkina, A G, Kostina, I E, Kochkareva, Iu B

“…The use of imatinib mesylate (Glivec) (Novartis Pharma AG, Switzerland) that is the drug of choice in treating patients with chronic myeloid leukemia (CML) has…”
Get full text